Patients with HER2-negative breast cancer that are found to have HER2-positive CTCs are allocated to the DETECT III study where efficacy of HER2-targeted therapy is observed as a means of controlling the metastatic process [54]. The gene discussed is ERBB2; the disease is breast cancer.